Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835602 | 1.00 | SIGMAR1 (0.55) | SIGMAR1EPHX1IDO1OPRK1OPRD1 | |
| SCHEMBL10797644 | 1.00 | SIGMAR1 (0.55) | SIGMAR1EPHX1IDO1OPRK1OPRD1 | |
| SCHEMBL8588435 | 0.91 | SIGMAR1 (0.51) | SIGMAR1IDO1OPRK1OPRD1 | |
| SCHEMBL8585890 | 0.90 | DPP7 (0.53) | SIGMAR1 | |
| SCHEMBL28380207 | 0.86 | SIGMAR1 (0.50) | SIGMAR1 | |
| SCHEMBL8586529 | 0.84 | MC4R (0.50) | SIGMAR1 | |
| SCHEMBL8588407 | 0.84 | LTA4H (0.47) | CYP3A4 | |
| SCHEMBL14495877 | 0.82 | SIGMAR1 (0.44) | SIGMAR1IDO1CYP3A4MAPT | |
| SCHEMBL4672917 | 0.82 | SIGMAR1 (0.58) | SIGMAR1 | |
| SCHEMBL8525894 | 0.82 | SIGMAR1 (0.58) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11897887-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-111712247-B | sGC stimulators | 塞科里昂医疗股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| EP-3589636-B1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230174477-A1 | METHODS FOR SYNTHESIS OF THE TRICYCLIC PROSTAGLANDIN D2 METABOLITE METHYL ESTER | PURDUE RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| US-20230174506-A1 | (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME | PURDUE RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| CN-110172051-B | IRE-1 alpha inhibitors | 复星弘创(苏州)医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-114728935-A | SHP2 inhibitor | IRBM股份公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-2203422-A1 | PHENYLPYRROLIDINE COMPOUNDS | Ferrer Internacional, S.A. (ES) | 2010-07-07 | — | — | EP | disclosed |
| EP-2178486-A2 | PACKAGING KIT FOR STATINS AND COMPOSITIONS THEREOF | Ranbaxy Laboratories Limited (IN) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009053441-A1 | PHENYLPYRROLIDINE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053443-A2 | INDANE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053444-A1 | COMPOUNDS OF 2,3-DIHYDRO-BENZOFURAN | FERRER INTERNACIONAL, S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
| US-20090071855-A1 | PACKAGING FOR AMORPHOUS STATINS AND COMPOSITIONS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2009-03-19 | — | — | US | disclosed |
| WO-2009024889-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A HMG-COA REDUCTASE INHIBITOR AND EZETIMIBE | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009019668-A2 | PACKAGING KIT FOR STATINS AND COMPOSITIONS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-12 | — | — | WO | disclosed |
| EP-1905424-A2 | Pharmaceutical composition comprising stabilized statin particles | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| US-20070202159-A1 | PHARMACEUTICAL COMPOSITION COMPRISING STABILIZED STATIN PARTICLES | RANBAXY LABORATORIES LIMITED (IN) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174506-A1 | (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME | NAAA, PAM, AANAT | SIGMAR1 2110/4885EPHX1 788/4885IDO1 199/4885 |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | SIGMAR1 2389/4885EPHX1 2561/4885IDO1 2624/4885 |
| US-11897887-B2 | sGC stimulators | GMPS, GUCY1A2, PDE2A | SIGMAR1 2156/4885EPHX1 1696/4885IDO1 4220/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | SIGMAR1 2389/4885EPHX1 2561/4885IDO1 2624/4885 |
| US-20230174477-A1 | METHODS FOR SYNTHESIS OF THE TRICYCLIC PROSTAGLANDIN D2 METABOLITE METHYL ESTER | PTGES2, PTGDR2, PTGES | SIGMAR1 3075/4885EPHX1 248/4885IDO1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.